Home | Business News | Browse by Publication | B | Business Wire

StemCells, Inc. Announces Initiatives to Advance Cell-Based Technologies for Pharmaceutical Industry and Research Applications.

Article Excerpt
PALO ALTO, Calif. -- StemCells, Inc. (NASDAQ:STEM) today announced organizational initiatives focused on growing its specialty SC Proven([R]) cell culture product business and advancing the development and commercialization of its central nervous system (CNS) cell-based assay platforms for use in drug screening and drug development. These initiatives reflect the Company's ongoing integration of the operations acquired from Stem Cell Sciences (SCS) Plc in April, and include new personnel appointments and a realignment of activities within the Company's Cambridge, UK and Palo Alto, California locations.

"The acquisition of the SCS operations solidifies our leadership position in the neural cell field and provides us with nearer-term commercial opportunities through non-therapeutic applications of our combined cell-based technology platforms," said Martin McGlynn, President and CEO of StemCells, Inc. "The actions we are now taking will centralize and focus specific platforms and personnel at specific sites to more effectively leverage our various capabilities. By aligning the appropriate expertise and resources, these initiatives will better position us to execute this strategic agenda and to realize the growth potential of our cell-based enabling technologies."

The Company is leveraging multiple stem cell technology platforms that include embryonic stem cells, induced pluripotent stem cells and tissue-derived (adult) stem cells. StemCells will refocus and...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!